ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00179049
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : December 15, 2008
Sponsor:
Information provided by:
Vanderbilt University

Brief Summary:
The investigators' hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of graft-versus-host disease.

Condition or disease
Hematopoietic Stem Cell Transplantation Graft vs Host Disease

Detailed Description:
The investigators' hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of graft-versus-host disease (GVHD) by determining the qualitative and quantitative changes in T regulatory cells throughout the transplant process. Their understanding of this can lead to new treatment strategies and improved clinical therapeutic implications.

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant (HSCT)
Study Start Date : April 2003
Actual Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients 18-70 years old undergoing either autologous transplant or allogeneic transplant for various hematologic conditions
Criteria

Inclusion Criteria:

  • Patients 18-70 years old undergoing either autologous transplant or allogeneic transplant for various hematologic conditions

Exclusion Criteria:

  • Patients < 18 or > 70 years old undergoing either autologous transplant or allogeneic transplant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00179049


Locations
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232-5505
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Adetola A Kassim, M.D. Vanderbilt University

Responsible Party: Adetola A. Kassim, MD, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00179049     History of Changes
Other Study ID Numbers: BMT 030261
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: December 15, 2008
Last Verified: December 2008

Keywords provided by Vanderbilt University:
T-Lymphocyte Subsets

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases